Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 42460 | 3.505 |
09:34 ET | 9924 | 3.5323 |
09:36 ET | 20935 | 3.51 |
09:38 ET | 13566 | 3.515 |
09:39 ET | 16860 | 3.56 |
09:41 ET | 1689 | 3.56 |
09:43 ET | 1490 | 3.56 |
09:45 ET | 3787 | 3.55 |
09:48 ET | 3759 | 3.5401 |
09:50 ET | 500 | 3.55 |
09:52 ET | 700 | 3.55 |
09:54 ET | 9448 | 3.56 |
09:56 ET | 300 | 3.58 |
09:57 ET | 800 | 3.555 |
09:59 ET | 2300 | 3.55 |
10:01 ET | 28187 | 3.555 |
10:03 ET | 11559 | 3.535 |
10:06 ET | 3159 | 3.525 |
10:08 ET | 13929 | 3.5098 |
10:10 ET | 3210 | 3.535 |
10:12 ET | 7230 | 3.525 |
10:14 ET | 3847 | 3.5499 |
10:15 ET | 1730 | 3.525 |
10:17 ET | 3997 | 3.525 |
10:19 ET | 2113 | 3.5393 |
10:21 ET | 100 | 3.535 |
10:24 ET | 11490 | 3.51 |
10:26 ET | 9682 | 3.525 |
10:28 ET | 2640 | 3.525 |
10:30 ET | 200 | 3.535 |
10:32 ET | 100 | 3.5394 |
10:35 ET | 6405 | 3.505 |
10:37 ET | 7830 | 3.52 |
10:39 ET | 30820 | 3.505 |
10:42 ET | 54697 | 3.515 |
10:44 ET | 6410 | 3.53 |
10:46 ET | 5670 | 3.555 |
10:48 ET | 2260 | 3.54 |
10:50 ET | 1000 | 3.525 |
10:51 ET | 200 | 3.535 |
10:53 ET | 1300 | 3.535 |
10:55 ET | 1320 | 3.535 |
10:57 ET | 3155 | 3.545 |
11:00 ET | 810 | 3.545 |
11:02 ET | 10700 | 3.541 |
11:04 ET | 3364 | 3.545 |
11:06 ET | 4727 | 3.535 |
11:08 ET | 3238 | 3.545 |
11:09 ET | 1400 | 3.545 |
11:11 ET | 400 | 3.545 |
11:13 ET | 3222 | 3.555 |
11:15 ET | 600 | 3.555 |
11:18 ET | 1267 | 3.565 |
11:20 ET | 400 | 3.565 |
11:22 ET | 1142 | 3.565 |
11:24 ET | 1600 | 3.57 |
11:26 ET | 2900 | 3.58 |
11:27 ET | 800 | 3.585 |
11:29 ET | 16477 | 3.59 |
11:31 ET | 3027 | 3.57 |
11:33 ET | 4770 | 3.575 |
11:36 ET | 500 | 3.575 |
11:38 ET | 3600 | 3.57 |
11:40 ET | 300 | 3.575 |
11:42 ET | 300 | 3.57 |
11:44 ET | 910 | 3.575 |
11:45 ET | 2696 | 3.57 |
11:47 ET | 4938 | 3.58 |
11:49 ET | 100 | 3.575 |
11:51 ET | 200 | 3.575 |
11:54 ET | 3165 | 3.585 |
11:56 ET | 620 | 3.58 |
11:58 ET | 110 | 3.575 |
12:00 ET | 100 | 3.575 |
12:02 ET | 1261 | 3.575 |
12:03 ET | 1163 | 3.575 |
12:05 ET | 14443 | 3.5511 |
12:07 ET | 100 | 3.555 |
12:09 ET | 679 | 3.559 |
12:12 ET | 300 | 3.555 |
12:14 ET | 1700 | 3.555 |
12:16 ET | 4653 | 3.555 |
12:18 ET | 4956 | 3.565 |
12:20 ET | 5673 | 3.565 |
12:21 ET | 2772 | 3.56 |
12:23 ET | 238 | 3.565 |
12:25 ET | 300 | 3.565 |
12:27 ET | 1000 | 3.565 |
12:30 ET | 1067 | 3.565 |
12:32 ET | 800 | 3.565 |
12:34 ET | 400 | 3.565 |
12:36 ET | 3804 | 3.57 |
12:38 ET | 16570 | 3.555 |
12:39 ET | 650 | 3.56 |
12:41 ET | 1500 | 3.565 |
12:43 ET | 900 | 3.565 |
12:45 ET | 10600 | 3.56 |
12:48 ET | 16062 | 3.555 |
12:50 ET | 1320 | 3.56 |
12:52 ET | 400 | 3.57 |
12:54 ET | 100 | 3.57 |
12:56 ET | 400 | 3.565 |
12:57 ET | 2771 | 3.555 |
12:59 ET | 1604 | 3.555 |
01:01 ET | 100 | 3.56 |
01:03 ET | 6204 | 3.555 |
01:06 ET | 6600 | 3.56 |
01:08 ET | 500 | 3.555 |
01:10 ET | 600 | 3.555 |
01:12 ET | 5128 | 3.555 |
01:14 ET | 1435 | 3.555 |
01:15 ET | 1750 | 3.555 |
01:17 ET | 5461 | 3.565 |
01:19 ET | 200 | 3.565 |
01:21 ET | 2960 | 3.5699 |
01:26 ET | 2186 | 3.565 |
01:28 ET | 5988 | 3.5894 |
01:30 ET | 5325 | 3.585 |
01:32 ET | 100 | 3.585 |
01:33 ET | 1400 | 3.585 |
01:35 ET | 10709 | 3.575 |
01:37 ET | 7626 | 3.57 |
01:39 ET | 1567 | 3.56 |
01:42 ET | 3128 | 3.565 |
01:44 ET | 702 | 3.56 |
01:46 ET | 2408 | 3.555 |
01:48 ET | 1221 | 3.55 |
01:50 ET | 104 | 3.555 |
01:51 ET | 12063 | 3.53 |
01:53 ET | 606 | 3.535 |
01:55 ET | 1624 | 3.535 |
01:57 ET | 2423 | 3.54 |
02:00 ET | 1204 | 3.535 |
02:02 ET | 1000 | 3.54 |
02:04 ET | 328 | 3.5345 |
02:06 ET | 5046 | 3.53 |
02:08 ET | 2600 | 3.515 |
02:09 ET | 6116 | 3.53 |
02:11 ET | 1095 | 3.53 |
02:13 ET | 2000 | 3.53 |
02:15 ET | 656 | 3.5392 |
02:18 ET | 938 | 3.535 |
02:20 ET | 2403 | 3.54 |
02:22 ET | 1000 | 3.535 |
02:24 ET | 100 | 3.54 |
02:26 ET | 300 | 3.535 |
02:27 ET | 5981 | 3.52 |
02:29 ET | 2960 | 3.535 |
02:33 ET | 444 | 3.535 |
02:36 ET | 1127 | 3.535 |
02:38 ET | 4873 | 3.52 |
02:40 ET | 602 | 3.52 |
02:42 ET | 737 | 3.521 |
02:44 ET | 604 | 3.52 |
02:47 ET | 400 | 3.525 |
02:49 ET | 100 | 3.525 |
02:51 ET | 1046 | 3.525 |
02:54 ET | 369 | 3.521 |
02:56 ET | 2850 | 3.53 |
02:58 ET | 100 | 3.535 |
03:00 ET | 388 | 3.535 |
03:02 ET | 300 | 3.54 |
03:03 ET | 900 | 3.535 |
03:05 ET | 1161 | 3.5308 |
03:07 ET | 2316 | 3.545 |
03:09 ET | 12077 | 3.525 |
03:12 ET | 8582 | 3.525 |
03:14 ET | 1300 | 3.525 |
03:16 ET | 2616 | 3.535 |
03:18 ET | 700 | 3.535 |
03:20 ET | 20517 | 3.55 |
03:21 ET | 2108 | 3.545 |
03:23 ET | 10718 | 3.55 |
03:25 ET | 3800 | 3.55 |
03:27 ET | 11816 | 3.541 |
03:30 ET | 2200 | 3.54 |
03:32 ET | 4208 | 3.545 |
03:34 ET | 9789 | 3.555 |
03:36 ET | 2411 | 3.56 |
03:38 ET | 1200 | 3.56 |
03:39 ET | 1200 | 3.5505 |
03:41 ET | 19468 | 3.59 |
03:43 ET | 2100 | 3.59 |
03:45 ET | 3691 | 3.59 |
03:48 ET | 21053 | 3.605 |
03:50 ET | 1200 | 3.605 |
03:52 ET | 13578 | 3.625 |
03:54 ET | 28547 | 3.64 |
03:56 ET | 23384 | 3.64 |
03:57 ET | 41783 | 3.635 |
03:59 ET | 51527 | 3.63 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 550.1M | -11.6x | --- |
Stoke Therapeutics Inc | 704.1M | -5.7x | --- |
Immunome Inc | 725.6M | -2.2x | --- |
AnaptysBio Inc | 684.6M | -4.0x | --- |
SS Innovations International Inc | 725.6M | -31.0x | --- |
Praxis Precision Medicines Inc | 707.6M | -2.6x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $550.1M |
---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-0.31 |
Book Value | $0.44 |
P/E Ratio | -11.6x |
Price/Sales (TTM) | 55.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.